Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antimir-134
- Development stage
- Preclinical
- Lead developer
- Preclinical research groups led by David C. Henshall and collaborators at academic institutions
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intracerebroventricular, Ex Vivo (human Brain Slice), Possibly Intrathecal (future Human Application)
01
Overview
antimir-134 is a synthetic antisense oligonucleotide designed to inhibit microRNA-134 (miR-134), a non-coding RNA implicated in the pathophysiology of epilepsy, particularly drug-resistant epilepsy. By specifically binding and silencing miR-134, antimir-134 reduces neuronal hyperexcitability, suppresses evoked and spontaneous seizures, and demonstrates neuroprotective effects by reducing seizure-induced neuronal damage and astrogliosis in preclinical animal models and human brain tissue ex vivo[1][3][5][6]. The therapy is being developed primarily as a disease-modifying agent for epilepsy, and recent advances suggest durable effects following a single dose, with potential application for other central nervous system disorders.
- Other names
- ant-134ant134ant 134antagomir-134antagomir134antagomir 134anti-miR-134anti-miR134anti-miR 134antimiR-134antimiR134antimiR 134
Beyond the preview
Go deeper on antimir-134.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antimir-134.